Catherine Leblanc

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

N. Ostermann, C. Schnell, Toshio Shimizu, 2022, Cancer discovery.

Abstract P124: JDQ443, a covalent irreversible inhibitor of KRAS G12C, exhibits a novel binding mode and demonstrates potent anti-tumor activity and favorable pharmacokinetic properties in preclinical models

D. Erdmann, N. Ostermann, C. Schnell, 2021, Poster Presentations - Proffered Abstracts.

Identification of novel anti-amoebic pharmacophores from kinase inhibitor chemotypes

D. Kyle, F. Gamarro, D. González-Pacanowska, 2023, Frontiers in Microbiology.

Chemical Optimization of CBL0137 for Human African Trypanosomiasis Lead Drug Discovery

Baljinder Singh, M. Pollastri, A. Purmal, 2023, Journal of medicinal chemistry.

Combinatorial chemistry as a tool for drug discovery.

C. Leblanc, M. Whittaker, C D Floyd, 1999, Progress in medicinal chemistry.

JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors.

N. Ostermann, R. Wilcken, S. Brachmann, 2022, Journal of medicinal chemistry.